Stock Scorecard
Stock Summary for Oncocyte Corporation (OCX) - $2.48 as of 4/27/2024 7:49:47 AM EST
Total Score
10 out of 29
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for OCX
| Positive earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for OCX
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for OCX
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 |
Bonus Criteria for OCX
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Latest News for for OCX
Financial Details for OCX
Company Overview |
|
|---|---|
| Ticker | OCX |
| Company Name | Oncocyte Corporation |
| Country | USA |
| Description | OncoCyte Corporation, a molecular diagnostics company, researches, develops, and markets proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company is headquartered in Irvine, California. |
| Sector Name | LIFE SCIENCES |
| Industry Name | IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES |
| Most Recent Quarter | 12/31/2023 |
| Next Earnings Date | 5/9/2024 |
Stock Price History |
|
| Last Day Price | 2.48 |
| Last Day Price Updated | 4/27/2024 7:49:47 AM EST |
| Last Day Volume | 17,697 |
| Average Daily Volume | 108,068 |
| 52-Week High | 6.20 |
| 52-Week Low | 2.08 |
| Last Price to 52 Week Low | 19.23% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 223.26 |
| Sector PE | 56.64 |
| 5-Year Average PE | -42.86 |
| Free Cash Flow Ratio | 3.49 |
| Industry Free Cash Flow Ratio | 37.01 |
| Sector Free Cash Flow Ratio | 30.65 |
| Current Ratio Most Recent Quarter | 1.49 |
| Total Cash Per Share | 0.71 |
| Book Value Per Share Most Recent Quarter | 2.48 |
| Price to Book Ratio | 0.59 |
| Industry Price to Book Ratio | 11.27 |
| Sector Price to Book Ratio | 22.15 |
| Price to Sales Ratio Twelve Trailing Months | 14.89 |
| Industry Price to Sales Ratio Twelve Trailing Months | 5.80 |
| Sector Price to Sales Ratio Twelve Trailing Months | 5.17 |
Share Statistics |
|
| Total Shares Outstanding | 13,338,100 |
| Market Capitalization | 33,078,488 |
| Institutional Ownership | N/A |
Dividends |
|
| Ex-Dividend Date | N/A |
| Last Dividend Amount | 0.00 |
| Current Dividend Amount | 0.00 |
| Dividend Aristocrat? | False |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | 61.89% |
| Reported EPS 12 Trailing Months | -3.37 |
| Reported EPS Past Year | -2.12 |
| Reported EPS Prior Year | -3.98 |
| Net Income Twelve Trailing Months | -27,781,000 |
| Net Income Past Year | -27,781,000 |
| Net Income Prior Year | -72,902,000 |
| Quarterly Revenue Growth YOY | 14.60% |
| 5-Year Revenue Growth | 0.00% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 9,432,000 |
| Total Cash Past Year | 9,432,000 |
| Total Cash Prior Year | 20,393,000 |
| Net Cash Position Most Recent Quarter | 8,858,000 |
| Net Cash Position Past Year | 8,119,000 |
| Long Term Debt Past Year | 1,313,000 |
| Long Term Debt Prior Year | 1,313,000 |
| Total Debt Most Recent Quarter | 574,000 |
| Equity to Debt Ratio Past Year | 0.94 |
| Equity to Debt Ratio Most Recent Quarter | 0.97 |
| Total Stockholder Equity Past Year | 20,468,000 |
| Total Stockholder Equity Prior Year | 34,292,000 |
| Total Stockholder Equity Most Recent Quarter | 20,468,000 |
Options |
|
| Put/Call Ratio | 0.00 |
| Has Options | False |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | -0.13 |
| MACD Signal | -0.10 |
| 20-Day Bollinger Lower Band | 2.42 |
| 20-Day Bollinger Middle Band | 2.96 |
| 20-Day Bollinger Upper Band | 3.49 |
| Beta | 0.78 |
| RSI | 38.47 |
| 50-Day SMA | 3.45 |
| 200-Day SMA | 34.04 |
System |
|
| Modified | 4/27/2024 7:49:51 AM EST |